Skip to main content
. Author manuscript; available in PMC: 2016 Aug 11.
Published in final edited form as: Arch Pharm (Weinheim). 2013 Jan;346(1):23–33. doi: 10.1002/ardp.201200334

Table 2.

PDE5 inhibitory activity of tetrahydro-β-carboline-hydantoins (520).

Compd R Chirality PDE5 % inhibition at 10 μma) PDE5 inhibition IC50 (μm)b)
5 –C2H5 5S, 11aR 99 0.2
6 –C2H5 5R, 11aR 66 4.8
7 –C2H5 5R, 11aS 78 2
8 –C2H5 5S, 11aS 99 0.16
9 –(CH2)3CH3 5S, 11aR 99 0.17
10 –(CH2)3CH3 5R, 11aR <60 ND
11 –(CH2)3CH3 5R, 11aS <60 ND
12 –(CH2)3CH3 5S, 11aS 92 0.47
13 –C–(CH3)3 5S, 11aR 97 0.39
14 –C–(CH3)3 5R, 11aR <60 ND
15 –C–(CH3)3 5R, 11aS <60 ND
16 –C–(CH3)3 5S, 11aS 90 1
17 –CH2–CH=CH2 5S, 11aR 96 0.29
18 –CH2–CH=CH2 5R, 11aR 67 5.4
19 –CH2–CH=CH2 5R, 11aS <60 ND
20 –CH2–CH=CH2 5S, 11aS 97 0.32
a)

Calculated from triplicate values.

b)

Calculated from 10 concentrations, each with double replicates.